Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats

Katja Savolainen1 · Jouni Ihalainen1 · Aaro J. Jalkanen1 · Markus M. Forsberg1

Received: 3 April 2018 / Accepted: 21 November 2018 / Published online: 10 December 2018
© The Author(s) 2018

Abstract
Rationale Social withdrawal is a core feature of the negative symptoms of schizophrenia. Currently available pharmacotherapies have only limited efficacy towards the negative symptoms, i.e., there is a significant unmet medical need in the treatment of these symptoms.

Objective We wanted to confirm whether selective adrenergic α2C receptor (AR) antagonist therapy could ameliorate acute phencyclidine (PCP)-induced schizophrenia-like social interaction deficits in rats, and to compare the effects of an α2C AR antagonist to another putative therapeutic alternative, an α7 nicotinic acetylcholine receptor (nAChR) partial agonist, as well against three commonly used atypical antipsychotics.

Methods Here, we used acute PCP administration and modified a protocol for testing social interaction deficits in male Wistar rats and then used this model to compare the effects of an α2C AR antagonist (ORM-13070 0.3 and 1.0 mg/kg s.c.) with an α7 nAChR partial agonist (EVP-6124 0.3 mg/kg s.c.) and three atypical antipsychotics (clozapine 2.5 mg/kg i.p., risperidone 0.04 and 0.08 mg/kg s.c., olanzapine 0.125 and 0.5 mg/kg s.c.) on social interaction behavior.

Results Acute PCP (1.5 mg/kg s.c.) produced robust and reproducible deficits in social interaction behavior without affecting locomotor activity. The selective α2C AR antagonist significantly ameliorated PCP-induced social interaction deficits. In contrast, neither the partial α7 nAChR agonist nor any of the three atypical antipsychotics were able to reverse the behavioral deficits at the selected doses.

Conclusion Our findings confirm that α2C AR antagonism is a potential mechanism for the treatment of the negative symptoms of schizophrenia.

Keywords α2C adrenergic receptor antagonist · α7 nicotinic acetylcholine receptor partial agonist · Atypical antipsychotics · Rat · Schizophrenia · Social interaction deficit

Introduction
Schizophrenia is a severe psychiatric disorder affecting approximately 1% of the population. Its symptoms consist of several domains, including positive symptoms (e.g., hallucinations, delusions, incoherence in speech and behavior), negative symptoms (e.g., deficits in social interaction, blunted affect, amotivation, anhedonia), and cognitive deficits (e.g., impairments in attention, memory, and executive functions). Social withdrawal is a core feature of the negative symptoms and it emerges during the early prodromal stage, persisting throughout the course of the illness (Gururajan et al. 2010; Wilson and Koenig 2014). Currently available pharmacological psycho-therapies mainly affect the positive symptoms of schizophrenia. Clearly, there is a significant unmet medical need in the treatment of its negative symptoms as both classical and atypical antipsychotics have shown only limited efficacy in their alleviation (Kirkpatrick et al. 2006; Hanson et al. 2010; Sarkar et al. 2015).

Several lines of research are ongoing to establish novel treatment concepts and drug targets for the negative symptoms of schizophrenia. Currently, many potential drug targets are under evaluation, with one of the most interesting being...
modulation of the adrenergic \( \alpha_{2C} \) receptor (AR) function. The \( \alpha_{2C} \) ARs have been associated with the treatment of schizophrenia in studies with transgenic mouse models (Scheinin et al. 2001; Svensson 2003), and the recent discovery of \( \alpha_2 \) AR subtype selective compounds has allowed more in-depth investigations on the effects of the \( \alpha_{2C} \) AR in different preclinical models, and recently also in humans (Uys et al. 2017).

In preclinical schizophrenia models, the \( \alpha_{2C} \) AR antagonists have shown some promising non-typical-like efficacy against acute phencyclidine (PCP)-induced prelapse inhibition (Sallinen et al. 2007, 2013a) and social interaction deficits in rats (Sallinen et al. 2013a). In addition to \( \alpha_{2C} \) AR, the \( \alpha_7 \) nicotinic acetylcholine receptor (nAChR) has been considered as one of the most promising schizophrenia drug targets, this being partly attributable to the evidence of dysfunctional nAChRs in schizophrenia (for a review, see Wallace and Bertrand 2015). The \( \alpha_7 \) nAChR agonists and positive allosteric modulators (PAMs) have been reported to alleviate the negative and cognitive symptoms associated with schizophrenia in acute ketamine-induced rat models (Nikiforuk et al. 2016; Ptasiewicz et al. 2017) and subchronic PCP mouse models (Pedersen et al. 2014). Furthermore, \( \alpha_7 \) nAChR partial agonists have shown efficacy against the negative symptoms also in schizophrenic patients as an add-on therapy with antipsychotics, although the main focus of those studies was on cognitive functions (Freedman et al. 2008; Lieberman et al. 2013; Keefe et al. 2015).

Preclinical development of novel pharmacotherapies for schizophrenia strongly relies on the use of valid animal models. The social interaction test, where two unfamiliar rodents are placed in a test environment and the time spent in social interactions is measured (File and Hyde 1978), is commonly utilized as a preclinical model for social functioning (Wilson and Koenig 2014), a characteristic often disturbed in schizophrenia. Psychotomimetic agents, such as N-methyl-D-aspartate (NMDA) receptor antagonists, PCP, and ketamine, are able to induce all domains of schizophrenia-like symptoms in healthy individuals as well as exacerbating the symptoms of patients with schizophrenia (Luby et al. 1959; Cohen et al. 1962; Itil et al. 1967; Krystal et al. 1994). NMDA antagonists interfere with social interaction behavior also in rodents (Gururajan et al. 2010; Wilson and Koenig 2014). Thus, NMDA antagonists are considered to possess good face validity as pharmacological models of schizophrenia, and PCP is one of the most widely used compounds for induction of schizophrenia-like symptoms in rodents. Nonetheless, both subchronic (followed by a drug-free period) (e.g., Sams-Dodd 1996; Pedersen et al. 2014) and acute (e.g., Corbett et al. 1995; Sams-Dodd 1997; Bruins Slot et al. 2005; Sallinen et al. 2013a) PCP administrations have been used to induce social interaction deficits. Acute PCP is typically administered either as a single dose (e.g., Corbett et al. 1995; Boulay et al. 2004; Sallinen et al. 2013a) or combined with a 2- to 4-day pretreatment period to adapt animals to the nonspecific effects of PCP (e.g., Sams-Dodd 1997; Pouzet et al. 2002; Bruins Slot et al. 2005). However, it has also been postulated that this kind of pretreatment is unnecessary when low PCP doses are being used (Boulay et al. 2004). Therefore, an acute low dose PCP administration protocol could provide a straightforward method to screen for the efficacy of novel drug candidates.

The goal of the present study was to confirm whether selective \( \alpha_{2C} \) AR antagonist therapy could ameliorate acute PCP-induced schizophrenia-like social interaction deficits in rats. Furthermore, we compared the effects of an \( \alpha_{2C} \) AR antagonist to another putative therapeutic alternative, an \( \alpha_7 \) nAChR partial agonist, as well against three commonly used atypical antipsychotics clozapine, risperidone, and olanzapine, which all possess \( \alpha_{2C} \) AR antagonistic properties. To achieve these goals, we first modified a simple and straightforward social interaction test protocol in rats based on an acute PCP administration to evoke schizophrenia-like social interaction deficits.

### Materials and methods

#### Experimental animals

Male Wistar rats (RccHan:WIST, Laboratory Animal Centre, University of Eastern Finland, Kuopio, Finland, and Harlan Laboratories, The Netherlands and USA; age 10–11 weeks), were used in the social interaction test. The rats were housed in groups of two in stainless steel cages (285 × 485 × 200 mm) under controlled laboratory conditions with 12:12 h light/dark cycle (lights on at 7.00 a.m., temperature 21 ± 2 °C, relative humidity 55 ± 15%). Food (2016S Teklad, Harlan Laboratories, Indianapolis, IN, USA) and water were available ad libitum except during the social interaction test session. The animal testing was performed during the light phase of the day (between 8.00 a.m. and 5.00 p.m.). All experiments were performed in accordance with European Union guidelines (Directive 2010/63/EU and guidelines 2007/526/EC) and approved by the National Animal Experiment Board of Finland.

#### Drugs and treatments

Phencyclidine hydrochloride (PCP; 1-(1-Phenylcyclohexyl)piperidine hydrochloride) and clozapine were purchased from Tocris Bioscience (Bristol, UK). Olanzapine and risperidone were purchased from Sigma-Aldrich (St. Louis, MO, USA). An \( \alpha_7 \) nAChR partial agonist EVP-6124 hydrochloride (also known as encenicline hydrochloride; (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride) was purchased from MedChem Express (Princeton, NJ, USA). An \( \alpha_{2C} \) AR antagonist ORM-13070
(1-[(S)-1-(2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]-4-(3-methoxy-methylpyrordin-2-yl)-piperazine; C_{20}H_{25}N_{3}O_{3}; MW 355.44) was provided by Orion Pharma (Espoo, Finland). ORM-13070 is a brain penetrating and highly selective α2C antagonist (binding affinity for α2C over α2A is over 28), which has been screened for binding to more than 100 other potential receptors and targets; on them, ORM-13070 displayed either weak or no activity (Arponen et al. 2014). A radiolabeled form ([11C]-ORM-13070) has been used as a PET tracer also in human subjects (Luoto et al. 2014; Lehto et al. 2015a, b, c, 2016).

PCP and EVP-6124 were dissolved in physiological saline (doses refer to the hydrochloride form). Clozapine, risperidone, and olanzapine were dissolved in physiological saline with a minimum amount of 0.1 M HCl. ORM-13070 was dissolved in a mixture of 15% polyethylene glycol 400 and 85% Glucosteril 50 mg/ml. The pH of the solution was adjusted to 4–5 with 1 M HCl. PCP (1.15 and 1.5 mg/kg s.c.), risperidone (0.04 and 0.08 mg/kg s.c.) and olanzapine (0.125 and 0.5 mg/kg s.c.) with their corresponding vehicle solutions were administered in a volume of 5 ml/kg; clozapine (2.5 mg/kg i.p.) and EVP-6124 (0.3 mg/kg s.c.) in a volume of 2 ml/kg; and ORM-13070 (0.3 and 1.0 mg/kg s.c.) in a volume of 1 ml/kg. The PCP dose range for the dose optimization experiment was selected on the basis of the literature (Corbett et al. 1995; Sams-Dodd 1996; Boulay et al. 2004; Sallinen et al. 2013a), taking into account the fact that a dose of 2 mg/kg already affects locomotor activity and induces stereotypical behavior and ataxia in rats (Castellani and Adams 1981; Sams-Dodd 1996; Boulay et al. 2004). The doses for clozapine (Corbett et al. 1995; Maehara et al. 2011), risperidone (Sams-Dodd 1997), and olanzapine (Corbett et al. 1995; Sallinen et al. 2013a) were chosen on the basis of previous rat studies with NMDA antagonists. The dose selection for EVP-6124 was based on the published literature (Prickaerts et al. 2012; Pedersen et al. 2014; Huang et al. 2014) and for ORM-13070 on our pilot experiments.

Social interaction test

The experimental animals had at least 1 week to acclimatize to the animal facilities prior to the testing procedure. The rats were adapted to handling on three times (separation, weighing, marking), and transferred into single cages 4–7 days before testing to increase the social interaction behavior (Niesink and van Ree 1982). The rats were randomly assigned into treatment groups. An open field arena (600 × 600 × 400 mm, illumination at the floor level 55–65 lx; Samplastic Oy, Kuopio, Finland), made from gray polyvinyl chloride, was used in the social interaction test. A digital video camera was mounted above each of the four arenas used in the study. On the test day, a pair of unfamiliar rats (matched body weights within 15 g) receiving the same pharmacological treatment, were placed in an unfamiliar open field arena and their behavior was recorded for 10 min in 1-min sections (Media Recorder, Noldus Information Technology, Wageningen, the Netherlands). All treatments and their corresponding vehicles were given 45 min prior to testing except EVP-6124 and risperidone, which were given 60 and 75 min prior to testing, respectively. The arenas were wiped with 20% ethanol between test sessions.

An experimenter blind to the treatments analyzed manually social interaction behavior for each pair of rats in the treatment groups using EthoVision XT v. 8.5 software (Noldus Information Technology). Sniffing the conspecific’s snout or parts of the body (including the anogenital region), following, walking around partner, climbing over or under, and mutual grooming were considered as social interaction whereas passive social contact or aggressive behavior were not. The locomotor activity of individual animals was analyzed automatically with EthoVision XT v. 8.5 software.

Data analysis and statistics

A 7-min period between 3 and 10 min of each trial was analyzed (see the “Results” section). No animals were excluded from the data analysis. All values are presented as mean ± standard error of mean (SEM). Statistical analyses were performed using IBM SPSS Statistics software v. 21 (IBM Finland, Helsinki, Finland). The statistical significance of the differences between the treatments in social interaction and locomotor activity was assessed using one-way analysis of variance (ANOVA) followed by Tukey post-hoc test for group comparisons. The differences were considered to be statistically significant at the p < 0.05 level.

Results

Optimization of acute PCP dose inducing social interaction deficits

First, we optimized the acute PCP dose to induce social interaction deficits without affecting the locomotor activity of the rats. Interestingly, the initial minute-to-minute analysis of the behavioral data showed that there were no group differences in the social interaction times between PCP-treated (1.15 or 1.5 mg/kg) and control rats in the first 3 min of the 10-min test session (F_{2,18} = 2.02, p > 0.1) (Fig. 1a). Thus, to reduce the effects of nonspecific disturbing factors and to improve the sensitivity of the model, we examined only the time period between 3 and 10 min in all analyses. During this time period, acute PCP (1.15 and 1.5 mg/kg) significantly affected social interaction behavior (F_{2,18} = 7.89, p < 0.01) (Fig. 1a). The post-hoc analysis revealed that already the lower PCP dose 1.15 mg/kg significantly reduced the time spent in social
**ORM-13070 ameliorates acute PCP-induced deficits in social interaction behavior**

After optimizing the PCP dose and modifying the social interaction study protocol, we examined the effects of an α�C AR antagonist ORM-13070 on PCP-induced social interaction deficits. A significant overall difference was observed in the social interaction time after the treatments (F3,79 = 11.96, p < 0.001) (Fig. 2). The post-hoc analysis revealed that ORM-13070 1.0 mg/kg significantly ameliorated the PCP-induced deficits by increasing the social interaction time by 49% (p < 0.01). ORM-13070 0.3 mg/kg had no significant effect on PCP-induced social interaction deficits (p > 0.7) and no further studies were conducted with this dose. ORM-13070 had no effect on locomotor activity (Table 1).

The effect of ORM-13070 1.0 mg/kg on PCP-induced social interaction was assessed in three independent experiments to confirm the repeatability of the initial finding. These replicates confirmed that the effect of ORM-13070 was highly robust and repeatable, since a significant overall difference was observed in social interaction time after the treatments in all independent experiments (EVP-6124: F2,24 = 11.16, p < 0.001; F2,25 = 8.89, p < 0.01; and F2,24 = 6.06, p < 0.01, respectively), and the post-hoc analysis revealed that ORM-13070 at 1.0 mg/kg dose significantly ameliorated the PCP-induced deficits by increasing the social interaction time by 53% (p < 0.05), 53% (p < 0.05), and 40% (p < 0.05), respectively, compared to the corresponding PCP groups.

**EVP-6124 and atypical antipsychotics have no effect on the acute PCP-induced deficits in social interaction behavior**

Next, we compared the effects of the α�C AR antagonist ORM-13070 to those of an αC nAChR partial agonist EVP-6124, and to three atypical antipsychotics clozapine, risperidone, and olanzapine. Neither EVP-6124 nor any of the three tested antipsychotics were able to reverse the PCP-induced deficits in the social interaction behavior (Fig. 3a–d). In confirmation of the above findings, the main effect of the treatment was observed, as PCP administration significantly reduced the social interaction time in all four experiments (EVP-6124: F2,24 = 11.16, p < 0.001, Fig. 3a; clozapine: F2,24 = 5.67, p < 0.01, Fig. 3b; risperidone: F3,37 = 13.19, p < 0.001, Fig. 3c; olanzapine: F3,37 = 12.92, p < 0.001, Fig. 3d). However, the post-hoc analysis revealed that none of the compounds affected the PCP-induced reduction in the social interaction time (EVP-6124 0.3 mg/kg: p > 0.8; clozapine 2.5 mg/kg: p > 0.8; risperidone...
0.04 mg/kg: \( p > 0.9 \); risperidone 0.08 mg/kg: \( p > 0.4 \); olanzapine 0.125 mg/kg: \( p > 0.4 \); olanzapine 0.5 mg/kg: \( p > 0.8 \). Clozapine 2.5 mg/kg and the higher doses of risperidone (0.08 mg/kg) and olanzapine (0.5 mg/kg) significantly decreased locomotor activity compared to the corresponding PCP groups by 63% (clozapine: \( F_{2,51} = 36.38, \ p < 0.001 \)), 47% (risperidone: \( F_{3,80} = 16.12, \ p < 0.001 \)), and 48% (olanzapine: \( F_{3,78} = 13.62, \ p < 0.01 \)), respectively (Table 1).

### Discussion

PCP is commonly used to induce schizophrenia-like social interaction deficits, but no validated acute low dose PCP administration protocols that could be used for drug screening purposes in early drug development have been published. Therefore, we first modified a feasible social interaction rat model based on acute PCP administration for the assessment of the negative schizophrenia-like symptoms (Sallinen et al. 2013a). Single PCP doses between 1.0–2.0 mg/kg have been used to induce social interaction deficits in rats (Corbett et al. 1995; Boulay et al. 2004; Savage et al. 2011; Sallinen et al. 2013a). However, PCP already at a dose of 2.0 mg/kg has been shown to induce nonspecific effects, such as stereotypy, ataxia and hyperactivity, mimicking some of the positive symptoms of schizophrenia and also affecting the social interaction of the animals (Castellani and Adams 1981; Sams-Dodd 1996; Boulay et al. 2004). These nonspecific effects were recently verified also by our functional MRI study which revealed the diffuse disrupting effects of PCP on rat brain connectivity at doses \( \geq 2.0 \) mg/kg (Paasonen et al. 2017).

### Table 1

| Dose 1 | ORM-13070 | EVP-6124 | Clozapine | Risperidone | Olanzapine |
|--------|-----------|----------|-----------|-------------|------------|
| 0.3    | 0.3       | 2.5      | 0.04      | 0.125       | 0.125      |
| 1.0    | n/a       | n/a      | n/a       |             | 0.08       |

| Dose 2 |
|--------|
| 0.3    |
| 2.5    |
| n/a    |

| SAL + Vehicle | 4318 ± 162 (52) | 4254 ± 141 (18) | 4192 ± 180 (18) | 3973 ± 107 * (28) | 4517 ± 211 * (26) |
| PCP 1.5 + Vehicle | 3777 ± 187 (50) | 3617 ± 118 (18) | 3871 ± 340 (18) | 3161 ± 200 (28) | 3379 ± 301 (28) |
| PCP 1.5 + Dose 1 | 3679 ± 516 (14) | 4290 ± 296 (18) | 1434 ± 199 *** (18) | 2612 ± 466 (14) | 2997 ± 440 (14) |
| PCP 1.5 + Dose 2 | 3566 ± 171 (50) | n/a | n/a | 1686 ± 221 *** (14) | 1756 ± 173 ** (14) |

\* \( p < 0.05 \), \* \( p < 0.01 \), \* \( p < 0.001 \) vs. PCP 1.5-treated group (Tukey post hoc). n/a not available, PCP phencyclidine, SAL saline
In the present study, both selected PCP doses (1.15 and 1.5 mg/kg) significantly reduced the time that the rats spent in social interaction but had no effect on locomotor activity, suggesting that the selected doses of PCP were able to mimic the social withdrawal characteristic of schizophrenia. Thus far, acute single PCP doses lower than 1.5 mg/kg have been successfully used only in experimental set-ups with a reversed light-dark cycle (Sams-Dodd 1996; Boulay et al. 2004; Sallinen et al. 2013a). In our study, a normal light-dark cycle and no preceding habituation to the test environment were used in order to increase the throughput of the test. The improved sensitivity of the present study protocol in detecting social withdrawal under a normal light-dark cycle may be explained by the fact that only the time period between 3 and 10 min was used in the data analysis. Our minute-to-minute analysis revealed that the initial habituation to the new test environment disturbed the social interaction behavior during the first minutes of the experiments. By excluding the first 3 min from each trial, the test measured more specifically the social interaction behavior, thus increasing the test’s sensitivity.

Next, we compared the effects of a selective \( \alpha_{2C} \) AR antagonist and various pharmacotherapies on the social interaction behavior. The \( \alpha_{2C} \) AR antagonist ORM-13070 significantly ameliorated acute PCP-induced social interaction deficits, whereas, the \( \alpha_1 \) nAChR partial agonist and three atypical antipsychotics were ineffective. The favorable effect of the \( \alpha_{2C} \) AR antagonist, ORM-13070, is in accordance with earlier studies conducted with another \( \alpha_{2C} \) AR antagonist, ORM-10921, which was able to totally reverse the acute PCP-induced social interaction deficits in rats (Sallinen et al. 2013a). Furthermore, it has been shown that \( \alpha_{2C} \) AR antagonists ameliorate also positive and cognitive deficits associated with schizophrenia in PCP-induced and neurodevelopmental rat models (Sallinen et al. 2007, 2013a; Uys et al. 2016). ORM-12741, another highly selective \( \alpha_{2C} \) AR antagonist (\( \alpha_{2C}/\alpha_{2A} \) ratio 100) pharmacologically closely resembling ORM-13070, has entered clinical trials assessing its effects on cognitive functions (Sallinen et al. 2013b; Rinne et al. 2017). As far as we are aware, however, the efficacy of this compound on social interaction deficits has not been evaluated. Nevertheless, such studies would be highly interesting since the clinical trials have shown that ORM-12741 can be safely administered to humans. One possible mechanism to account for the ability of \( \alpha_{2C} \) AR antagonists to exert effects on negative symptoms might be the modulation of the firing activity of the prefrontal dopaminergic neurons originating from the ventral tegmental area (Sallinen et al. 2013a). The hypofunction in these neurons has been closely associated with pronounced negative symptoms in schizophrenia patients (Winograd-Gurvich et al. 2006; Schwartz et al. 2012), and the functional connectivity of the prefrontal cortical area was significantly changed by acute low PCP dose (2.0 mg/kg s.c.) (Paasonen et al. 2017). The \( \alpha_{2C} \) antagonist ORM-10921 increased dopamine release in the medial prefrontal cortex of rats (Sallinen et al. 2013a), which could partly explain the beneficial effects of \( \alpha_{2C} \) AR antagonists on PCP-induced cortical dysfunction. On the other hand, \( \alpha_{2C} \) ARs might directly contribute to the regulation of DA release at the terminal level in the medial prefrontal cortex (Ihalainen and Tanila 2002). Furthermore, \( \alpha_{2C} \) AR antagonists may modify striatal GABAergic output (Holmberg et al. 1999; Zhang and Ordway 2003), thus affecting multiple transmitter systems contributing to dopamine turnover in prefrontal cortical regions. However, the precise mechanism by which \( \alpha_{2C} \) AR antagonists exert their effects remains to be resolved.

This is the first study to assess the effects of the \( \alpha_7 \) nAChR partial agonist, EVP-6124, in acute PCP-induced social interaction deficits in rats. We detected no effect at selected dose, although EVP-6124 and a full \( \alpha_7 \) nAChR agonist, TC-5619, have been reported to be able to reverse subchonic PCP-induced deficits in social interaction behaviors in mice (Pedersen et al. 2014). Furthermore, type I and type II \( \alpha_7 \) nAChR PAMs together with an orthosteric agonist and partial agonist have all alleviated acute ketamine-induced social interaction deficits in rats (Nikiforuk et al. 2016; Potasiewicz et al. 2017). This discrepancy can be explained by the differences in experimental models and the use of various NMDA antagonists. In addition, a rat in vivo microdialysis study investigating the effects of EVP-6124 on various neurotransmitter levels found evidence for an inverted U-shaped dose-response profile for EVP-6124 (Huang et al. 2014), suggesting that the dose-responsiveness of EVP-6124 may vary between models. Therefore, more in-depth studies should be undertaken to investigate the dose-responsiveness of EVP-6124 in NMDA antagonist-induced social interaction model.

Atypical antipsychotics, such as clozapine, risperidone and olanzapine, have shown some efficacy in reversing social interaction deficits in rat models (e.g., Corbett et al. 1995; Sams-Dodd 1996, 1997) although also opposite results have been reported (e.g., Corbett et al. 1995; Sams-Dodd 1997; Boulay et al. 2004; Sallinen et al. 2013a). Classical antipsychotics, which act mainly as dopamine D2 receptor antagonists, have no effect on PCP-induced social interaction deficits (e.g., Corbett et al. 1995; Sams-Dodd 1996; Boulay et al. 2004; Bruins Slot et al. 2005). These contradictory results agree with clinical studies indicating that atypical antipsychotics, acting through multiple receptor systems in addition to dopaminergic D2 receptors (e.g., serotonergic, adrenergic, and cholinergic), ameliorate the negative symptoms of schizophrenia, although their efficacy is far from satisfactory (Kirkpatrick et al. 2006; Hanson et al. 2010; Sarkar et al. 2015). As there is no drug of choice for the treatment of negative symptoms in patients, no true positive control compound exists. Thus far, it is not known which mechanism of the multimodal effects of atypical antipsychotics accounts for their efficacy against the negative
symptoms of schizophrenia. Notably, \( \alpha_{2C} \) AR antagonism is a common characteristic of certain atypical antipsychotics postulated to have beneficial effects on the negative symptoms, and especially, a high antagonistic \( \alpha_{2C}/D_2 \) ratio, seems to be favorable (Kalkman and Loetscher 2003; Brosda et al. 2014). The three antipsychotics tested in the present study all have higher affinity for the \( \alpha_{2C} \) ARs than for the \( \alpha_{2A} \) ARs (\( \alpha_{2C}/\alpha_{2A} \) ratios: clozapine 4.2; risperidone 116; olanzapine 16.2) (Brosda et al. 2014). However, only clozapine has a \( \alpha_{2C}/D_2 \) ratio \( \geq 1 \), which is considered necessary if the \( \alpha_{2C} \) AR antagonism is to possess any clinical relevance (Kalkman and Loetscher 2003).

The effects of atypical antipsychotics on NMDA antagonist-induced deficits in social interaction behavior in preclinical schizophrenia models are variable and seem to be dependent on several factors, e.g., on the dosing regimen of the drugs and the applied NMDA antagonist. For example, acute clozapine appears to be relatively ineffective in PCP models (Sams-Dodd 1998; Boulay et al. 2004; Bruins Slot et al. 2005; Sallinen et al. 2013a, however, see Corbett et al. 1995), but subchronic administration may exert some positive effects (Sams-Dodd 1996, 1998). Similarly, risperidone and olanzapine lack efficacy against PCP-induced social interaction deficits (Corbett et al. 1995; Sams-Dodd 1997; Boulay et al. 2004; Pedersen et al. 2014) although some positive results, especially with higher or repeated doses of risperidone, have also been reported (Corbett et al. 1995; Sams-Dodd 1997; Pouzet et al. 2002). We also tested higher doses of risperidone and olanzapine (0.08 mg/kg s.c. and 0.5 mg/kg s.c., respectively), but they both tended to further reduce the social interaction time and substantially decreased the locomotor activity of the PCP-treated rats (Table 1). As clozapine significantly decreased the locomotor activity already at the tested dose without affecting social interaction behavior, higher doses were not tested. One can hypothesize that significant \( \alpha_{2} \) antagonism and reversal of PCP-induced social interaction deficit without undesired motor side effects is difficult to achieve by acute clozapine. In fact, pharmacokinetic modeling data by Li et al. (2014) indicates that predicted \( \alpha_{2} \) occupancy is only approximately 30% at plasma clozapine levels bringing >90% muscarinic \( M_1 \) and histamine \( H_1 \) occupancy and approximately 50% \( D_2 \) occupancy. Interestingly, an antipsychotic drug, aripiprazole, has shown some efficacy in preclinical studies against PCP-induced social interaction deficits (Bruins Slot et al. 2005; Snigdha and Neill 2008). However, in the study of Tarland et al. (2018), aripiprazole was unable to reverse the social interaction deficits. Aripiprazole has strikingly different receptor binding profile compared to atypical antipsychotics used in this study, including agonistic effect on \( D_2 \) receptors and relatively high affinity for serotonergic 5-HT\(_{1A}\) receptors, which may explain its positive effects on social interaction behavior (Bruins Slot et al. 2005; Snigdha and Neill 2008). Altogether, our data agree with clinical findings where atypical antipsychotics have shown conflicting effects on the negative symptoms of schizophrenia, and furthermore, subchronic treatment is required in order to reveal their antipsychotic properties (Kirkpatrick et al. 2006; Sarkar et al. 2015). Thus, more work will be required to establish the effects of subchronically administered antipsychotics in the present social interaction test protocol.

In conclusion, an acute low dose PCP induces highly robust and repeatable schizophrenia-like social interaction deficits in Wistar rats. Most importantly, we confirmed that a selective \( \alpha_{2C} \) AR antagonist, ORM-13070, could ameliorate the PCP-induced social interaction deficits in rats, supporting the hypothesis that \( \alpha_{2C} \) AR antagonism is a potential mechanism for the treatment of the negative symptoms of schizophrenia.

**Acknowledgments** The authors wish to thank Juuso Leikas M.Sc. (Pharm.), Henna Koivisto M.Sc., and Elina Hämäläinen M.Sc. for the help in performing social interaction experiments; Mrs. Jaana Leskinen for excellent technical assistance in performing drug formulations; Ewen MacDonald Ph.D. for revising the language; and Orion Pharma for kindly providing ORM-13070 as a pharmacological tool in this study.

**Funding Information** Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital. The present study was funded by the Finnish Funding Agency for Innovation (TEKES)/the European Regional Development Fund (ERDF) (Grant Agreement 70051/10) and The Finnish Cultural Foundation.

**Compliance with ethical standards**

**Research involving animals** All experiments involving animals were performed in accordance with European Union guidelines (Directive 2010/63/EU and guidelines 2007/526/EC) and approved by the National Animal Experiment Board of Finland (license numbers ESAVI/1836/04.10.07/2013 and ESAVI-2037/04.10.03/2011).

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

Arponen E, Helin S, Marjamäki P, Grönroos T, Holm P, Löyttyniemi E, Någren K, Scheinin M, Haaparanta-Solin M, Sallinen J, Solin O (2014) A PET tracer for brain \( \alpha_{2C} \) adrenoceptors, (\( \alpha \)C-ORM-13070: radiosynthesis and preclinical evaluation in rats and knockout mice. J Nucl Med 55:1171–1177. https://doi.org/10.2967/jnumed.113.135574

Boulay D, Depoortère R, Louis C, Perrault G, Griebel G, Soubrié P (2004) SSR181507, a putative atypical antipsychotic with
doamphetamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropsychopharmacology 46:1121–1129. https://doi.org/10.1016/j.neuropharm.2004.02.008

Brosda J, Jantschak F, Petz HH (2014) α2-adrenergic receptors are targets for antipsychotic drugs. Psychopharmacology 231:801–812. https://doi.org/10.1007/s00213-014-3459-8

Bruins Slot LA, Kleven MS, Newman-Tancredi A (2005) Effects of novel antipsychotics with mixed D2(1) antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropsychopharmacology 49:996–1006. https://doi.org/10.1016/j.neuropharm.2005.05.013

Castellani S, Adams PM (1981) Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol 73:143–154

Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS (1962) Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysyric acid diethyamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking. Arch Gen Psychiatry 6:395–401

Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize noncompetitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67–74

File SE, Hyde JR (1978) Can social interaction be used to measure anxiety? Br J Pharmacol 62:19–24

Freedman R, Olincy A, Buchanan RW, Gold JM, Johnson L, Allenworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutzick J, Pender V, Martin LF, Stevens KE, Wagner GD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165:1040–1047. https://doi.org/10.1176/appi.ajp.2008.07071135

Gururajan A, Taylor DA, Malone DT (2010) Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav Pharmacol 21:690–709. https://doi.org/10.1097/FBP.0b013e2823367df

Hanson E, Healey K, Wolf D, Kohler C (2010) Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep 12:563–571. https://doi.org/10.1007/s11920-010-0148-0

Holmberg M, Scheinin M, Kurose H, Miettinen R (1999) Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurones: comparison of radioligand binding and immunohistochemistry. Neuroscience 93:1323–1333

Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G, Meltzer HY (2014) The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology 231:4541–4551. https://doi.org/10.1007/s00213-014-3596-0

Ihalainen JA, Tanila H (2002) In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse prefrontal cortex. Eur J Neurosci 15:1789–1794

Itil T, Keskiner A, Kiremitci N, Holden JM (1967) Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J 12:209–212

Kalkman HO, Loetscher E (2003) α2C-adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol 462:33–40

Keefe RSE, Meltzer HA, Dgeluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC (2015) Randomized, double-blind, placebo-controlled study of encenilcine, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 40:3053–3060. https://doi.org/10.1038/npp.2015.176

Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32:214–219. https://doi.org/10.1093/schbul/sbj053

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Henninger GR, Bowers MB, Charney DS (1994) Subanesthetic responses of the noncompetitive NMDA antagonist, ketamine, in humans. Psychophotometric, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214

Lehto J, Hirvonen MM, Johansson J, Kemppainen J, Luoto P, Naukkarinen T, Oikonen V, Arponen E, Rouuri J, Sallinen J, Scheinin H, Vuorilehto L, Finnema SJ, Hallidin C, Rinne JO, Scheinin M (2015a) Validation of [(11)C]ORM-13070 as a PET tracer for alpha2C-adrenoceptors in the human brain. Synapse 69:172–181. https://doi.org/10.1002/syn.21798

Lehto J, Johansson J, Vuorilehto L, Luoto P, Arponen E, Scheinin H, Rouuri J, Scheinin M (2015b) Sensitivity of [(11)C]ORM-13070 to increased extracellular noradrenaline in the CNS - a PET study in humans. Psychopharmacology 232:4169–4178. https://doi.org/10.1007/s00213-015-3941-y

Lehto J, Virta JR, Oikonen V, Roivainen A, Luoto P, Arponen E, Helen S, Hietamäki J, Holopainen A, Kailajärvi M, Petlonen JM, Rouuri J, Sallinen J, Virtanen K, Volanen I, Scheinin M, Rinne JO (2015c) Test-retest reliability of [(11)C]ORM-13070 in PET imaging of alpha2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging 42:120–127. https://doi.org/10.1007/s00259-014-2899-z

Lehto J, Scheinin A, Johansson J, Marjamäki P, Arponen E, Scheinin H, Scheinin M (2016) Detecting a dexmedetomidine-evoked reduction of noradrenaline release in the human brain with the alpha2C-adrenoceptor PET ligand [(11)C]ORM-13070. Synapse 70:57–65. https://doi.org/10.1002/syn.21872

Li CH, Stratford RE, Velez de Mendizábal N, Cremers TIFH, Pollock BG, Mulsant BH, Remington G, Biess RR (2014) Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. J Transl Med 12:203. https://doi.org/10.1186/1479-8876-12-203

Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA (2013) A randomized exploratory trial of an α7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Psychopharmacology 38:968–975. https://doi.org/10.1007/s00213-012-2259

Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81:363–369

Luoto P, Suilamo S, Oikonen V, Arponen E, Helen S, Heruttuinen J, Hietamäki J, Holopainen A, Kailajärvi M, Petlonen JM, Rouuri J, Sallinen J, Scheinin M, Virta J, Virtanen K, Volanen I, Roivainen A, Rinne JO (2014) (3H)-ORM-13070, a novel PET ligand for brain αC-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. Eur J Nucl Med Mol Imaging 41:1947–1956. https://doi.org/10.1007/s00259-014-2782-y

Maehara S, Okuda S, Ohta H (2011) Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions. Brain Res Bull 86:146–154. https://doi.org/10.1016/j.brainresbull.2011.08.004

Niesink RJ, van Ree JM (1982) Short-term isolation increases social interactions of male rats: a parametric analysis. Physiol Behav 29:819–825

Nikiforuk A, Kos T, Holuj M, Potasiewicz A, Popik P (2016) Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats. Neuropsychopharmacology 101:389–400. https://doi.org/10.1016/j.neuropsychopharmacology.2015.07.034

Paasonen J, Salo RA, Ihalainen J, Leikas IV, Savolainen K, Lehtonen M, Forsberg MM, Grünh O (2017) Dose-response effect of acute phencyclidine on functional connectivity and dopamine levels, and their association with schizophrenia-like symptom classes in rats. Neuropsychopharmacology 119:15–25. https://doi.org/10.1016/j.neuropsychopharmacology.2017.03.024

Springer
Potasiewicz A, Ho, Pedersen CS, Sørensen DB, Parachikova AI, Plath N (2014) PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia. Behav Brain Res 273:63–72. https://doi.org/10.1016/j.bbr.2014.07.023

Potasiewicz A, Hohaj M, Kos T, Popik P, Arias HR, Nikiforuk A (2017) 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats. Neuropsychopharmacology 113:188–197. https://doi.org/10.1016/j.neuropharm.2016.10.002

Potouz B, Didriksen M, Amt J (2002) Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav 71:655–665

Prickaerts J, Van Goethem NP, Chesworth R, Shapiro G, Boess FG, Pouzet B, Didriksen M, Arnt J (2002) Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav 71:655–665

Prickaerts J, Van Goethem NP, Chesworth R, Shapiro G, Boess FG, Pouzet B, Didriksen M, Arnt J (2002) Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav 71:655–665

Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, Murphy M, Rioradan H, Scheinin M, Soininen H, Rouru J (2017) Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer’s disease. Alzheimers Dement Transl Res Clin Interv 3:1–9. https://doi.org/10.1016/j.trci.2016.11.004

Salininen J, Högblad J, Engström M, Lehtimäki J, Virtanen H, Sirviö J, Wurster S, Savola-J-M, Haapelmann A (2007) Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenergic receptor antagonist JP-1302. Br J Pharmacol 150:391–402. https://doi.org/10.1038/sj.bjp.0707005

Salininen J, Holappa J, Koivisto A, Kuokkanen K, Chapman H, Lehtimäki J, Piepponen P, Mijatovic J, Tanila H, Virtanen H, Sirviö J, Haapelmann A (2013a) Pharmacological characterisation of a structurally novel α2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol 113:239–249. https://doi.org/10.1111/bcpt.12090

Salininen J, Rouuri J, Lehtimäki J, Marjamäki P, Haaparanta-Solin M, Arponen E, Helin S, Soilin O, Tarazi F, Shahid M (2013b) ORM-12741: receptor pharmacology of a novel alpha2c-adrenergic receptor subtype selective antagonist with multi-therapeutic potential. Neuropsychopharmacology 38:S558

Sams-Dodd F (1996) Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 7:3–23

Sams-Dodd F (1997) Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8:196–215

Sams-Dodd F (1998) A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine.

Neuropsychopharmacology 18:293–304. https://doi.org/10.1016/S0893-133X(97)00161-9

Sarkar S, Hillner K, Velligan DI (2015) Conceptualization and treatment of negative symptoms in schizophrenia. World J Psychiatry 5:352–361. https://doi.org/10.5498/wjp.v5.i4.352

Savage S, Kehr J, Olson L, Mattsson A (2011) Impaired social interaction and enhanced sensitivity to phencyclidine-induced deficits in novel object recognition in rats with cortical cholinergic denervation. Neuroscience 195:60–69. https://doi.org/10.1016/j.neuroscience.2011.08.027

Scheinin M, Salininen J, Haapelmann A (2001) Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci 68:2277–2285

Schwartz TL, Sachdeva S, Stahl SM (2012) Glutamate neurotranscircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 3:195. https://doi.org/10.3389/fphar.2012.00195

Snigdha S, Neill JC (2008) Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 191:26–31. https://doi.org/10.1016/j.bbr.2008.03.018

Svensson TH (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuro-Psychopharmacol Biol Psychiatry 27:1145–1158. https://doi.org/10.1016/j.pnpbp.2003.09.009

Tarland E, Franke RT, Fink H, Pertz HH, Brosda J (2018) Effects of 2-bromoteguride, a dopamine D2 receptor partial agonist, on cognitive dysfunction and social aversion in rats. Psychopharmacology 235:99–108. https://doi.org/10.1007/s00213-017-4747-x

Uys M, Shahid M, Salininen J, Dreyer W, Cockeran M, Harvey BH (2016) The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol. Prog Neuro-Psychopharmacol Biol Psychiatry 71:108–116. https://doi.org/10.1016/j.pnpbp.2016.07.002

Uys MM, Shahid M, Harvey BH (2017) Therapeutic potential of selectively targeting the α2C-adrenoceptor in cognition, depression, and schizophrenia—new developments and future perspective. Front Psychiatry 8:144. https://doi.org/10.3389/fpsyg.2017.00144

Wallace TL, Bertrand D (2015) Neuronal α7 nicotinic receptors as a target for the treatment of schizophrenia. Int Rev Neurobiol 124:79–111. https://doi.org/10.1016/bs.irn.2015.08.003

Wilson CA, Koenig JI (2014) Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 24:759–773. https://doi.org/10.1016/j.eunl.2013.11.008

Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB (2006) Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson’s disease. Brain Res Bull 70:312–321. https://doi.org/10.1016/j.brainresbull.2006.06.007

Zhang W, Ordway GA (2003) The alpha2C-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res 112:24–32